Telix Pharmaceuticals Limited (ASX: TLX) announced a significant licensing agreement under which the company will receive an upfront payment of $40 million.

In addition, if certain research and development, regulatory, and commercialization milestones are achieved in the future, Telix will also be eligible to receive up to a total of $2.1 billion. The agreement also includes royalty arrangements based on future product sales. This transaction highlights the value of Telix's leading technology in the field of radiopharmaceuticals and the enormous market potential of its products.